Guideline conform initial monotherapy increases in patients with focal epilepsy: A population-based study on German health insurance data

Seizure

Volumn 41, Issue , 2016, Pages 9-15

  Ertl, Julia ^a   Hapfelmeier, Jana ^a   Peckmann, Thomas ^b   Forth, Bernhard ^b   Strzelczyk, Adam ^c,d  

^a Gesundheitsforen Leipzig   (Germany)

^b ALK SCHERAX Arzneimittel GmbH   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Clinical practice guideline; Epidemiology; Epilepsy; Seizure

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LEVETIRACETAM; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT; ETIRACETAM; PIRACETAM;

ADULT; ARTICLE; FEMALE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; GERMANY; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; EPILEPSIES, PARTIAL; PUBLIC HEALTH; STANDARDS; STATISTICS AND NUMERICAL DATA;

ANTICONVULSANTS; EPILEPSIES, PARTIAL; FEMALE; GERMANY; GUIDELINES AS TOPIC; HUMANS; MALE; NATIONAL HEALTH PROGRAMS; PIRACETAM; RETROSPECTIVE STUDIES;

EID: 84978427231     PISSN: 10591311     EISSN: 15322688     Source Type: Journal    
DOI: 10.1016/j.seizure.2016.07.001     Document Type: Article

References (54)

1. [1] Forsgren, I., Beghi, E., Ekman, M., Cost of epilepsy in Europe. Eur J Neurol 12:Suppl 1 (2005), 54–58.
2. [2] Strzelczyk, A., Reese, J.P., Dodel, R., Hamer, H.M., Cost of epilepsy: a systematic review. Pharmacoeconomics 26 (2008), 463–476.
3. [3] Smeets, V.M., Van Lierop, B.A., Vanhoutvin, J.P., Aldenkamp, A.P., Nijhuis, F.J., Epilepsy and employment: literature review. Epilepsy Behav 10 (2007), 354–362.
4. [4] Haag, A., Strzelczyk, A., Bauer, S., Kuhne, S., Hamer, H.M., Rosenow, F., Quality of life and employment status are correlated with antiepileptic monotherapy versus polytherapy and not with use of ``newer'' versus ``classic'' drugs: Results of the ``Compliant 2006'' survey in 907 patients. Epilepsy Behav 19 (2010), 618–622.
5. [5] Jacoby, A., Stigma, epilepsy, and quality of life. Epilepsy Behav 3 (2002), 10–20.
6. [6] Begley, C.E., Shegog, R., Iyagba, B., Chen, V., Talluri, K., Dubinsky, S., et al. Socioeconomic status and self-management in epilepsy: comparison of diverse clinical populations in Houston. Texas. Epilepsy Behav 19 (2010), 232–238.
7. [7] Jehi, L., Tesar, G., Obuchowski, N., Novak, E., Najm, I., Quality of life in 1931 adult patients with epilepsy: seizures do not tell the whole story. Epilepsy Behav 22 (2011), 723–727.
8. [8] Riechmann, J., Strzelczyk, A., Reese, J.P., Boor, R., Stephani, U., Langner, C., et al. Costs of epilepsy and cost-driving factors in children, adolescents, and their caregivers in Germany. Epilepsia 56 (2015), 1388–1397.
9. [9] Kwan, P., Brodie, M.J., Early identification of refractory epilepsy. N Engl J Med 342 (2000), 314–319.
10. [10] Kwan, P., Arzimanoglou, A., Berg, A.T., Brodie, M.J., Allen Hauser, W., Mathern, G., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51 (2010), 1069–1077.
11. [11] Beghi, E., Garattini, L., Ricci, E., Cornago, D., Parazzini, F., Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 45 (2004), 171–178.
12. [12] Hamer, H.M., Spottke, A., Aletsee, C., Knake, S., Reis, J., Strzelczyk, A., et al. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 47 (2006), 2165–2172.
13. [13] Jacoby, A., Buck, D., Baker, G., Mcnamee, P., Graham-Jones, S., Chadwick, D., Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia 39 (1998), 776–786.
14. [14] Tetto, A., Manzoni, P., Millul, A., Beghi, E., Garattini, L., Tartara, A., et al. The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res 48 (2002), 207–216.
15. [15] Strzelczyk, A., Nickolay, T., Bauer, S., Haag, A., Knake, S., Oertel, W.H., et al. Evaluation of health-care utilization among adult patients with epilepsy in Germany. Epilepsy Behav 23 (2012), 451–457.
16. [16] Larisch, A., Oertel, W.H., Eggert, K., Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practice. J Neurol 256 (2009), 1681–1688.
17. [17] Hasenbein, U., Schulze, A., Busse, R., Wallesch, C.W., Physicians' attitudes concerning guidelines. An empirical survey in neurologic clinics. Gesundheitswesen 67 (2005), 332–341.
18. [18] Marson, A.G., Al-Kharusi, A.M., Alwaidh, M., Appleton, R., Baker, G.A., Chadwick, D.W., et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007), 1016–1026.
19. [19] Marson, A.G., Al-Kharusi, A.M., Alwaidh, M., Appleton, R., Baker, G.A., Chadwick, D.W., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007), 1000–1015.
20. [20] Brodie, M.J., Perucca, E., Ryvlin, P., Ben-Menachem, E., Meencke, H.J., Levetiracetam Monotherapy Study, G., Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68 (2007), 402–408.
21. [21] Elger, C.E., Erster epileptischer Anfall und Epilepsien im Erwachsenenalter. Diener, H.C., Putzki, N., (eds.) Leitlinien für Diagnostik und Therapie in der Neurologie, 2008, Thieme Verlag, Stuttgart, 2–16.
22. [22] Noda, A.H., Reese, J.P., Berkenfeld, R., Dennig, D., Endrass, G., Kaltofen, J., et al. Leitlinienumsetzung und Kosten bei neudiagnostizierter Epilepsie. Zeitschrift für Epileptologie 28 (2015), 304–310.
23. [23] Ernst, J.P., Steinhoff, B.J., Vademecum Antiepilepticum 2007/2008, Pharmakotherapie der Epilepsien. Hamburg, 2007.
24. [24] Dippel, F.W., Mäurer, M., Schinzel, S., Müller-Bohn, T., Larisch, K., Health Insurance Data Confirm High Prevalence of Multiple Sclerosis. Akt Neurol 42 (2015), 191–196.
25. [25] Jette, N., Reid, A.Y., Quan, H., Hill, M.D., Wiebe, S., How accurate is ICD coding for epilepsy?. Epilepsia 51 (2010), 62–69.
26. [26] Kwon, C.S., Liu, M., Quan, H., Wiebe, S., Mcchesney, J., Wirrell, E., et al. The incidence of injuries in persons with and without epilepsy–a population-based study. Epilepsia 51 (2010), 2247–2253.
27. [27] Tu, K., Wang, M., Jaakkimainen, R.L., Butt, D., Ivers, N.M., Young, J., et al. Assessing the validity of using administrative data to identify patients with epilepsy. Epilepsia 55 (2014), 335–343.
28. [28] St Germaine-Smith, C., Metcalfe, A., Pringsheim, T., Roberts, J.I., Beck, C.A., Hemmelgarn, B.R., et al. Recommendations for optimal ICD codes to study neurologic conditions: a systematic review. Neurology 79 (2012), 1049–1055.
29. [29] Reid, A.Y., St Germaine-Smith, C., Liu, M., Sadiq, S., Quan, H., Wiebe, S., et al. Development and validation of a case definition for epilepsy for use with administrative health data. Epilepsy Res 102 (2012), 173–179.
30. [30] Proposal for revised classification of epilepsies and epileptic, syndromes., Commission on Classification and Terminology of the International League Against, Epilepsy. Epilepsia 30 (1989), 389–399.
31. [31] Proposal for revised clinical and electroencephalographic classification of epileptic, seizures, From the Commission on Classification and Terminology of the International League Against, Epilepsy. Epilepsia 22 (1981), 489–501.
32. [32] Berg, A.T., Berkovic, S.F., Brodie, M.J., Buchhalter, J., Cross, J.H., Van Emde Boas, W., et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 51 (2010), 676–685.
33. [33] Hamer, H.M., Dodel, R., Strzelczyk, A., Balzer-Geldsetzer, M., Reese, J.P., Schoffski, O., et al. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany–a nationwide population-based study in children and adults. J Neurol 259 (2012), 2376–2384.
34. [34] Johannessen Landmark, C., Larsson, P.G., Rytter, E., Johannessen, S.I., Antiepileptic drugs in epilepsy and other disorders–a population-based study of prescriptions. Epilepsy Res 87 (2009), 31–39.
35. [35] Bolin, K., Berggren, F., Landtblom, A.M., Prevalence and cost of epilepsy in Sweden - a register-based approach. Acta Neurol Scand 131 (2015), 37–44.
36. [36] Steinhoff, B.J., Kurth, C., Dennig, D., Levetiracetam bei generalisierten Epilepsien des Erwachsenenalters. Zeitschrift für Epileptologie 25 (2012), 118–124.
37. [37] Johannessen Landmark, C., Fossmark, H., Larsson, P.G., Rytter, E., Johannessen, S.I., Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 95 (2011), 51–59.
38. [38] Strzelczyk, A., Haag, A., Reese, J.P., Nickolay, T., Oertel, W.H., Dodel, R., et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Epilepsy Behav 27 (2013), 433–438.
39. [39] Tsiropoulos, I., Gichangi, A., Andersen, M., Bjerrum, L., Gaist, D., Hallas, J., Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand 113 (2006), 405–411.
40. [40] Noda, A.H., Hermsen, A., Berkenfeld, R., Dennig, D., Endrass, G., Kaltofen, J., et al. Evaluation of costs of epilepsy using an electronic practice management software in Germany. Seizure 26 (2015), 49–55.
41. [41] National Institute for Health and Care Excellence (Nice) The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE clinical guideline 137. Issued: January 2012 last modified: January 2015; http://guidance.nice.org.uk/cg137.
42. [42] Pickrell, W.O., Lacey, A.S., Thomas, R.H., Lyons, R.A., Smith, P.E., Rees, M.I., Trends in the first antiepileptic drug prescribed for epilepsy between 2000 and 2010. Seizure 23 (2014), 77–80.
43. [43] Dixon, P.A., Kirkham, J.J., Marson, A.G., Pearson, M.G., National Audit of Seizure management in Hospitals (NASH): results of the national audit of adult epilepsy in the UK. BMJ Open, 5, 2015, e007325.
44. [44] Bruun, E., Virta, L.J., Kalviainen, R., Keranen, T., Choice of the first anti-epileptic drug in elderly patients with newly diagnosed epilepsy: A Finnish retrospective study. Seizure 31 (2015), 27–32.
45. [45] Karbach, U., Schubert, I., Hagemeister, J., Ernstmann, N., Pfaff, H., Hopp, H.W., Physicians' knowledge of and compliance with guidelines: an exploratory study in cardiovascular diseases. Dtsch Arztebl Int 108 (2011), 61–69.
46. [46] Reinecke, H., Unrath, M., Freisinger, E., Bunzemeier, H., Meyborg, M., Luders, F., et al. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart J 36 (2015), 932–938.
47. [47] Steinhoff, B.J., Bacher, M., Bucurenciu, I., Kornmeier, R., Kurth, C., Martin, P., et al. The impact of guidelines on the quality of MRI diagnostics in adult patients referred to a tertiary epilepsy centre. J Neurol 260 (2013), 3174–3175.
48. [48] Bien, C.G., Raabe, A.L., Schramm, J., Becker, A., Urbach, H., Elger, C.E., Trends in presurgical evaluation and surgical treatment of epilepsy at one centre from 1988-2009. J Neurol Neurosurg Psychiatry 84 (2013), 54–61.
49. [49] Strzelczyk, A., Zschebek, G., Bauer, S., Baumgartner, C., Grond, M., Hermsen, A., et al. Predictors of and attitudes toward counseling about SUDEP and other epilepsy risk factors among Austrian, German, and Swiss neurologists and neuropediatricians. Epilepsia 57 (2016), 612–620.
50. [50] Cabana, M.D., Rand, C.S., Powe, N.R., Wu, A.W., Wilson, M.H., Abboud, P.A., et al. Why don't physicians follow clinical practice guidelines?. A framework for improvement. Jama 282 (1999), 1458–1465.
51. [51] De Flon, P., Kumlien, E., Reuterwall, C., Mattsson, P., Empirical evidence of underutilization of referrals for epilepsy surgery evaluation. Eur J Neurol 17 (2010), 619–625.
52. [52] Lhatoo, S.D., Solomon, J.K., Mcevoy, A.W., Kitchen, N.D., Shorvon, S.D., Sander, J.W., A prospective study of the requirement for and the provision of epilepsy surgery in the United Kingdom. Epilepsia 44 (2003), 673–676.
53. [53] Forsgren, L., Beghi, E., Oun, A., Sillanpaa, M., The epidemiology of epilepsy in Europe - a systematic review. Eur J Neurol 12 (2005), 245–253.
54. [54] Fisher, R.S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J.H., Elger, C.E., et al. ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia 55 (2014), 475–482.